Company intelligence / Profile preview

Olatec Therapeutics LLC

New York City, New York, USAolatec.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Dapansutrile has demonstrated safety with no observed human toxicity in clinical trials. Positive Phase 2a proof-of-concept results were reported for acute gout flares showing reduction of inflammation mediated by IL‑1β. In heart failure patients, improvements in left ventricular ejection fraction and cardiopulmonary exercise time were observed without adverse cardiac effects. The compound is advancing into further Phase 2 studies including early Parkinson's disease supported by grants from Cure Parkinson's Foundation. Topical formulations have been tested successfully in osteoarthritis[1][4][6][7].

Therapeutic areas: PulmonologyCardiovascularRheumatologyEndocrinologyOncologyNeurology
Modalities: Small molecule oral therapeutics (NLRP3 inflammasome inhibitors)Oral selective NLRP3 antagonist compounds including dapansutrile and analogues
Industry: Biotech

Drug pipeline

3 assets

dapansutrile

2 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with Duke University among othersgrant support from Michael J. Fox Foundation for Parkinson’s Researchcollaboration with Cure Parkinson's Foundation[4][6]

Beyond the preview

Go deeper on Olatec Therapeutics LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olatec Therapeutics LLC.

Explore the full profile